Overview

Dupilumab in Chronic Spontaneous Urticaria

Status:
Unknown status

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy in reducing disease activity and safety of Dupilumab in adult patients with chronic spontaneous urticaria (CSU) who are symptomatic despite H1-antihistamine treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Charite University, Berlin, Germany

Collaborators:

Proinnovera GmbH
Sanofi

Treatments:

Antibodies, Monoclonal